Results 161 to 170 of about 33,038 (222)

Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival.

JAMA Netw Open
Büttner T, Klümper N, Ellinger J, Ritter M, Krausewitz P.   +4 more
europepmc   +1 more source

Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer. [PDF]

Prostate
Kawai T, Maki K, Taguchi S, Fujii Y, Tanaka T, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada D, Yamada Y, Takada T, Nakagawa T, Kume H.   +13 more
europepmc   +1 more source

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. [PDF]

Drugs Real World Outcomes
Bosch D, van der Velden KJM, Beeker A, van den Berg HP, Bergman AM, van der Doelen MJ, van den Eertwegh AJM, Hendriks MP, Kerkhofs TMA, van de Luijtgaarden ACM, Mehra N, van Moorselaar RJA, Tascilar M, Vervenne WL, Weijl NI, Uyl-de Groot CA, Mulders PFA, Kuppen MCP, van Oort IM.   +18 more
europepmc   +1 more source

Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer. [PDF]

Br J Cancer
Kondrup K, Iisager L, Salachan PV, Nørgaard M, Lamy P, Eeles R, Hansen TF, Osther PJS, Zedan AH, Borre M, Sørensen KD.   +10 more
europepmc   +1 more source

Correction: SLC7A11 upregulation via AR and NEDD4L ubiquitination contributes to ferroptosis inhibition and enzalutamide resistance in castration-resistant prostate cancer. [PDF]

Cell Death Dis
Tang M, Xue L, Wang B, Jiang Z, Li P, Bu H, Zhao C, Zhang Y, Liu S, Chen X, Liu B, Meng X, Li J.   +12 more
europepmc   +1 more source

Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer. [PDF]

EJNMMI Res
Ahmed EE, Andrews JR, Ahmed ME, Haloi R, Rhodes LA, Mahon M, Carter DA, Wei N, Thorpe MP, Johnson GB, Kwon ED, Kendi AT.   +11 more
europepmc   +1 more source

Quercetin Inhibits AKT Ser473 Phosphorylation and Disrupts AKT-Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Cells. [PDF]

Antioxidants (Basel)
Duprat F, Azócar-Plaza S, Castillo-Cáceres MP, Rivas Y, Sanzana-Rosas J, Pampaloni P, Olivas-Henríquez G, Toledo J, Villa JL, Bertinat R, Jara N, Vallejos-Almirall A, Salas A, González-Chavarría I.   +13 more
europepmc   +1 more source

Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report. [PDF]

Int Cancer Conf J
Terrano V, Perri E, Cioffo C, Mastroianni G, Palumbo MA, Ciardiello F, Troiani T, Napolitano S.   +7 more
europepmc   +1 more source

Case Report: [²²⁵Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma. [PDF]

Front Oncol
Musabaev I, Goryaynov S, Yu Kochetova T, Krylov V, Ivanov S.   +4 more
europepmc   +1 more source

Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression. [PDF]

J Clin Invest
Feng T, Xie N, Gao L, Jia Q, Kung SH, Morova T, Li Y, Wang L, Fazli L, Lacombe L, Guillemette C, Lévesque E, Lack NA, Qi J, Han B, Dong X.   +15 more
europepmc   +1 more source